Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program: Our Impact

 {Photo credit: Stanley Stephanus for SIAPS Namibia}Pehovelo Ndahangoudja (left), a registered nurse documents feedback on CBART from Know your Status CASG member Julia Sheepo (2nd from right) and leader Marian Ndahafo Lilonga (right) at Ndamono clinic, Onandjokwe district.Photo credit: Stanley Stephanus for SIAPS Namibia

Health leaders in Namibia had a geographic challenge in delivering antiretroviral (ARV) treatment. The country is among the most affected by the HIV and AIDS epidemic in Southern Africa, with an estimated HIV prevalence among adults of 16.9% as of 2014. Yet, in a vast country in which two-thirds of the people live in sparsely settled rural sites, how could these leaders make sure essential ARV treatment is accessible to those in need?

Photo: From left: Johnnie Amenyah of JSI, Gladys Tetteh, Francis Aboagye-Nyame, Dinah Tjipura, and Kwesi Eghan of the SIAPS Program attending the End-of-Program event on March 1, 2018 in Arlington, VA. (Santita Ngo/MSH) On Thursday, March 1, 2018, MSH held an end-of-program event for the USAID-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) program.

{Photo Credit: Liza Talukder}Jahidul Hasan works on the adverse drug event report.Photo Credit: Liza Talukder

The Directorate General of Drug Administration (DGDA)—with technical assistance from the USAID-funded SIAPS program, implemented by MSH—officially launched Bangladesh’s national pharmacovigilance (PV) program in 2013. After being first introduced at 20 private and public hospitals, and 13 pharmaceutical companies, the DGDA and SIAPS have organized trainings for focal persons to build their skills and knowledge on PV and increase adverse drug event (ADE) reporting.

{Photo Credit: Wezi Tjaronda}Olavi Shomongula shares his testimony with U.S. Ambassador to Namibia Thomas F. Daughton.Photo Credit: Wezi Tjaronda

A new electronic health tool developed by the USAID-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) program, implemented byMSH, is being used in more than 50 public health facilities in Namibia. This tool—the Facility Electronic Stock Card (FESC)—has noticeably expedited the dispensing of medication to patients. This was evident when the US Ambassador to Namibia H.E. Thomas F. Daughton visited the Intermediate Hospital Oshakati (IHO), which is in the populous Oshana region in the North-Central part of Namibia.

 {Photo courtesy of Sherri Haas}MSH staff at the Global Digital Health Forum 2017.Photo courtesy of Sherri Haas

Management Sciences for Health’s work across the digital health spectrum was shared at the Global Digital Health Forum 2017 (GDHF 2017) in Washington, D.C. December 4-6, 2017. The GDHF is the premier global conference on the use of digital technology for health in low- and middle-income countries. MSH is an Advisory Board Member of the Global Digital Health Network and contributed substantially to development of the conference. The theme this year was The Evolving Digital Health Landscape: Progress, Achievements, and Remaining Frontier.

{Photo credit: Warren Zelman}Photo credit: Warren Zelman

 

Health extension worker Lemlem Worku gives Zara Ahmed amoxicillin antibiotics for her 10 month old baby.Photo credit: UNICEF Ethiopia / CC BY-NC-ND

Devex has reported on the role of well-trained health workers in the fight against antimicrobial resistance (AMR). Increasing levels of AMR — a result of the misuse of drugs, poor-quality medication and improper prescriptions, among other factors — is a threat not only to people’s health, but also to the global economy, poverty levels, and the achievement of the Sustainable Development Goals.

A technician tests a child for malaria at a health center in Kinshasa, DRC.Photo Credit: Aubrey Clark

The USAID-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program, led by MSH, recently published the results of its activities in eight countries (Angola, Burundi, the Democratic Republic of the Congo (DRC), Ethiopia, Kenya, Guinea, Mali, and South Sudan) to control malaria.

 {Photo credit: Wezi Tjaronda (MSH/SIAPS Namibia)}Pharmacist in charge of the Facility Electronic Stock Card (FESC) at Oshakati Hospital, Tesema Zelalem (seated) shows the US Ambassador to Namibia, Thomas Daughton (right) and Senior Pharmacist of the hospital, Mesele Walellign a print out of available medicines in the pharmacy, from the FESC computer on July 13, 2017.Photo credit: Wezi Tjaronda (MSH/SIAPS Namibia)

The U.S. Ambassador to Namibia, H.E. Thomas Daughton, visited a hospital and clinic in the Oshana region of Namibia last week to unveil a new electronic stock card, an innovation that has greatly improved service delivery in the country.

 {Photo credit: SIAPS Namibia}ART Pharmacy in Oshikuku District Hospital, Omusati Region, Namibia.Photo credit: SIAPS Namibia

In a major advance against the spread of HIV, Namibia has approved the use of emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) to prevent HIV infection. The Namibian Medicines Regulatory Council (NMRC) approved a generic version of the medicine, Ricovir EM®, which is manufactured by Mylan Pharmaceuticals. It is used in combination with other antiretroviral medications to treat AIDS. When taken daily, it can reduce the risk of sexually transmitted HIV by more than 90%. To date, very few African countries have approved the regimen for use as pre-exposure prophylaxis, or PrEP.

Pages